Summary: In a 52-week, single-centre, open-label randomized trial of 34 obese adults with type 2 diabetes, once-weekly subcutaneous semaglutide reduced body mass index, waist circumference, and HbA1c and lowered LDL and non-HDL cholesterol while redistributing LDL and HDL subfractions toward a less atherogenic profile. Once-daily oral sitagliptin produced only modest glycaemic improvement. The abstract reports the direction of these findings as significant but provides no numeric effect estimates, confidence intervals, or p-values.
PICO Summary
| Element | Detail |
|---|---|
| Population | 34 obese adults with type 2 diabetes mellitus; a further 31 age- and body-weight-matched non-diabetic obese individuals served as controls. Single-centre, randomized, open-label design conducted in Hungary. |
| Intervention | Once-weekly subcutaneous semaglutide for 52 weeks (n = 18). |
| Comparison | Once-daily oral sitagliptin for 52 weeks (n = 16). A non-diabetic obese group (n = 31) provided a reference comparison. |
| Outcome | Semaglutide was reported to significantly reduce body mass index, waist circumference, and HbA1c, with reductions in LDL cholesterol and non-HDL cholesterol and a redistribution of LDL and HDL subfractions toward a less atherogenic profile. Sitagliptin produced only modest glycaemic improvement without substantial lipid change. Multivariate regression indicated that the lipoprotein subfraction changes were not explained by changes in body mass index or HbA1c. The abstract provides no numeric effect sizes, 95% confidence intervals, p-values, or absolute risk reduction or number-needed-to-treat figures. |
Expert Commentary
This small, single-centre, open-label randomized trial supports a directional verdict that once-weekly semaglutide improves lipoprotein subfraction quality beyond what is achieved with sitagliptin, and the observation that these changes were statistically independent of weight loss and glycaemic improvement is mechanistically interesting and consistent with a pleiotropic effect of GLP-1 receptor agonism. The verdict must, however, be read as hypothesis-strengthening rather than practice-changing. The principal limitation is statistical fragility: with only 18 patients given semaglutide and 16 given sitagliptin, the trial is underpowered for hard lipid endpoints, and because the abstract reports no effect sizes, confidence intervals, or p-values, the magnitude and precision of any benefit cannot be judged. The open-label design and the comparison of an injectable against an oral agent without placebo introduce further bias, and surrogate subfraction shifts measured by gel electrophoresis are not validated cardiovascular outcomes. Can I use this with my patients? Not yet as a reason to select semaglutide for lipid lowering specifically; it is reasonable reinforcement for an obese patient with type 2 diabetes already being considered for a GLP-1 receptor agonist on glycaemic and weight grounds. Larger, adequately powered, blinded trials reporting absolute lipid changes and event data are needed before lipoprotein remodelling becomes a prescribing rationale.
References
Tóth LI, Harsányi A, Csiha S, Molnár Á, Lőrincz H, Nagy AC, et al. Semaglutide improves lipid subfraction profiles in type 2 diabetes: insights from a one-year follow-up study. Int J Mol Sci. 2025;26(13):5951. doi:10.3390/ijms26135951
